Plain-English translation of NCT06305598 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new approach called bipolar androgen therapy for men with advanced prostate cancer that has become resistant to standard hormone-blocking treatments. The study will give you testosterone injections while you continue your regular prostate cancer medication (). Researchers want to see if this medication can help your cancer become sensitive to treatment again and improve your quality of life.
Some prostate cancers stop responding to standard hormone-lowering therapy over time. This study is exploring whether temporarily adding testosterone might trick the cancer cells into becoming responsive to treatment again, offering a new option for men in this difficult situation.
You likely qualify if…
You likely don't qualify if…
You would receive testosterone injections on the first day of each 4-week cycle for 3 cycles total, while continuing your regular prostate cancer medication as usual. Throughout the study, you'll have CT scans, bone scans, and possibly MRI scans and biopsies to track how the treatment is working. After the treatment phase ends, you'll have follow-up visits at 30 days and then every 3 months for up to 2 years to monitor your health and cancer response.
AI-generated summary from trial data · Jun 14, 2026 · Not medical advice
United States